Landmark study defines benefits of early HIV testing and treatment for infected infants

November 20, 2008

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. The study found that giving ART to HIV-infected infants beginning at an average age of 7 weeks made them four times less likely to die in the next 48 weeks, compared with postponing ART until signs of illness or a weakened immune system appeared--the standard of care when the study began.

These findings come from the "Children with HIV Early Antiretroviral Therapy" (CHER) study, the first Phase III randomized clinical trial to study the best time to begin ART in infants. Launched in South Africa in July 2005, CHER is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the departments of health of the Western Cape and Gauteng in South Africa.

"HIV devastates the nascent immune systems of infants very quickly, yet too many HIV-infected infants do not get tested for the virus, get tested too late or get tested but lack access to lifesaving antiretroviral drugs," says Anthony S. Fauci, M.D., the director of NIAID. "The results of CHER are a clarion call to scale up widespread early HIV testing of at-risk infants and to make ART immediately accessible to all infants who test positive."

Preliminary results of CHER, released in July 2007, showed that HIV-infected infants were four times less likely to die if given ART immediately after HIV diagnosis (http://www3.niaid.nih.gov/news/newsreleases/2007/cher.htm). This finding helped influence the World Health Organization (WHO) to change its guidelines for treating HIV-infected infants. The new guidelines, issued in April 2008, strongly recommend starting ART in children under age 1 immediately after HIV diagnosis, regardless of their state of health. An NIAID study to identify the best drug regimen for these highly vulnerable children is under way.

"The new WHO guidelines will profoundly improve the survival rate and quality of life of infants born with HIV," says Ed Handelsman, M.D., chief of the Pediatric Medicine Branch in NIAID's Division of AIDS. "We are excited that we know the best time to begin treating HIV-infected infants; the challenge now for the global community is to ensure that all HIV-infected infants who need ART receive it soon enough."

The CHER study team, lead by Avy Violari, FCPaed, and Mark F. Cotton, MMed PhD, recruited and enrolled 377 infants between 6 and 12 weeks of age who had confirmed HIV infection but normal immune system development. Originally, the infants were randomly assigned to one of three regimens: start ART immediately and continue for 40 weeks; start ART immediately and continue for 96 weeks; or defer ART until signs of clinical or immunological progression to AIDS appeared. The ART regimen consists of ritonavir-boosted lopinavir, zidovudine and lamivudine, provided by GlaxoSmithKline PLC of Britain and the South African Department of Health. CHER is being conducted at two locations in South Africa: the Perinatal HIV Research Unit of the University of Witwatersrand; and the Children's Infectious Diseases Clinical Research Unit of Tygerberg Children's Hospital and Stellenbosch University. These sites are collaborating with the Medical Research Council Clinical Trials Unit in London.

In June 2007, a data and safety monitoring board (DSMB) overseeing CHER found that the babies who received immediate ART were four times less likely to die than the babies whose treatment was deferred. This was true even though 66 percent of those in the deferred treatment arm had met the criteria for ART during the first 32 weeks of the trial and already had begun treatment. Consequently, the DSMB recommended, and NIAID agreed, to assess all the children in the deferred-treatment arm for potential initiation of ART.

The study measured the effectiveness of the treatment strategies by counting the number of babies who died or whose immune systems were not protected by the original ART regimen. After a median of 48 weeks, 10 of 252 infants (4 percent) in the immediate-treatment arms had died, as had 20 of 125 (16 percent) infants in the deferred-treatment arm. Thus, immediate ART reduced deaths by 75 percent. As a secondary measure of success or failure, CHER counted the number of infants who developed HIV-related disease. Such disease developed in 16 babies (6.3 percent) in the immediate-treatment arms and 32 babies (26 percent) in the deferred-treatment arm. Thus, the infants who received treatment immediately were more than four times less likely to develop HIV-related disease.

NIH/National Institute of Allergy and Infectious Diseases

---

---

	FDA panel votes yes for drug studies in HIV-infected infants. (Several Cautions Voiced).: An article from: Pediatric News by Kerri Wachter (Author) This digital document is an article from Pediatric News, published by International Medical News Group on April 1, 2003. The length of the article is 693 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: FDA panel votes yes for drug studies in HIV-infected infants. (Several Cautions Voiced). Author: Kerri Wachter Publication: Pediatric News (Magazine/Journal) Date: April 1, 2003 Publisher: International Medical News Group Volume: 37 Issue: 4 Page: 9(1) Distributed by Thomson...
	WHO Recommendations on the Management of Diarrhoea and Pneumonia in HIV Infected Infants and Children: Integrated Management of Childhood Illness (IMCI) by World Health Organization (Author) To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhea, malaria and ear infections, as well as common opportunistic infections and HIV-related co-morbidities. WHO is developing a series of guidelines on each of these conditions, following the GRADE approach. The document on the management of pneumonia and diarrhea in HIV-infected infants and children is the first of this series. The recommendations are similar to those for non infected children, but they cover specific aspects related to HIV infection. This publication is intended primarily for use by national advisory boards, national HIV/AIDS...
	Medical Management of Newborns, Infants and Children Born to HIV-Infected Mothers by HIV Services Unit (Author)
	Neurodevelopmental delay in infants infected with HIV: A longitudinal study from South Africa by Joanne Potterton (Author) HIV is neurotrophic and has been shown to invade the developing central nervous system and cause encephalopathy in young children. Infants infected with HIV in South Africa were assessed using the Bayley Scales of Infant Development ll. The children were severely delayed in both motor and cognitive development at baseline and caregivers recorded very high parenting stress levels. The children were randomised into two groups, an experimental and a control group. The children who received a basic home stimulation programme showed statistically significant improvements in motor and cognitive scores over a one year period. Despite these improvements the children remained delayed at the end of the study period. Children infected with HIV need long term management which includes physiotherapy.
	Nevirapine resistance in HIV-infected women and infants after exposure to nevirapine-based prophylaxis. by Jessica D Church (Author) Over 300,000 infants are HIV-infected each year, and the majority of HIV-infected pregnant women do not have access to any antiretroviral prophylaxis. The simplest option for prevention of vertical HIV transmission is the HIVNET012 regimen of a single-dose of nevirapine (SD NVP) to the mother in labor and SD NVP to the infant shortly after birth. This regimen drastically reduces the risk of mother-to-child transmission of HIV (MTCT), is easy to implement, and is more affordable than other regimens. One of the main disadvantages to the regimen is the emergence of NVP resistant variants in mothers and in infants who are HIV-infected despite prophylaxis. A variety of assays are available for detection of NVP resistance. Work in this dissertation shows that if the risk of resistance is...
	Clinical Companion for Wong's Essentials of Pediatric Nursing by Marilyn J. Hockenberry PhD RN-CS PNP-BC FAAN (Author), David Wilson MS RNC-NIC (Author) Carry all of the most essential knowledge on pediatric care in your pocket with the Clinical Companion for Wong's Essentials of Pediatric Nursing! This indispensable guide from the authors of the most trusted pediatric nursing textbook on the market includes need-to-know information for the clinical setting in a quick-reference format. Content on the procedures and diagnostic tests you're most likely to perform, plus brief discussions of over 130 commonly encountered childhood illnesses and disorders, makes this the perfect companion for practice. The History and Physical Assessment section includes atraumatic methods and age appropriate techniques.The Pain Assessment and Management section features pain scales and information on pharmacologic and nonpharmacologic management of...
	Infectious Diseases of the Fetus and Newborn: Expert Consult - Online and Print, 7e (INFECTIOUS DISEASES OF THE FETUS AND NEWBORN INFANT) by Jack S. Remington MD (Author), Jerome O. Klein MD (Author), Christopher B. Wilson MD (Author), Victor Nizet (Author), Yvonne Maldonado (Author) Infectious Diseases of the Fetus and Newborn Infant, written and edited by Drs. Remington, Klein, Wilson, Nizet, and Maldonado, remains the definitive source of information in this field. The 7th edition of this authoritative reference provides the most up-to-date and complete guidance on infections found in utero, during delivery, and in the neonatal period in both premature and term infants. Special attention is given to the prevention and treatment of these diseases found in developing countries as well as the latest findings about new antimicrobial agents, gram-negative infections and their management, and recommendations for immunization of the fetus/mother. Nationally and internationally recognized in immunology and infectious diseases, new associate editors Nizet and Maldonado...
	ANAC's Core Curriculum for HIV / AIDS in Nursing, Third Edition by Association of Nurses in AIDS Care (ANAC) (Author) The Association of Nurses in AIDS Care (ANAC) presents the essential information needed by every nurse working with HIV/AIDS patients in any setting. The text provides an educational framework for HIV/AIDS clinical content and serves those preparing for specialty certification in HIV/AIDS training. The text covers: A) Infection, transmission, and prevention B) Clinical management of a variety of patient types C) Symptomatic conditions and symptom management D) Special populations and E) Psychosocial concerns for patients. ANAC's Core Curriculum for HIV/AIDS Nursing, Third Edition includes the following new topics: Updates to the evidence basis underlying the nursing care of persons with HIV/AIDS; New issues and challenges including the care for pediatric patients and adults with giardia,...
	HIV And Social Work: A Practitioner's Guide (Psychosocial Issues of Hiv/Aids) by R Dennis Shelby (Author), David M Aronstein (Author), Bruce J Thompson (Author) As HIV/AIDS continue to plague societies around the world, more and more social workers encounter HIV-infected individuals and their families and friends who are searching for help and support. In HIV and Social Work: A Practitioner's Guide, experienced social workers share their practice wisdom, knowledge, and skills on a broad range of issues. Their words of wisdom will give you the willingness to follow problems through and the flexibility and creativity that are required when dealing with issues concerning HIV/AIDS. At the same time, you will achieve a sense of empowerment and optimism as you realize that there are things you can do--very specific kinds of help you can offer--that can make an enormous difference in the lives of people with HIV/AIDS and those who love and care for...
	Podemos evitar que las madres mueran y que los bebes se infecten por el VIH / We can avoid that mothers die and that infants infected by HIV (Spanish Edition) by World Health Organization (Author)